MX2023004017A - Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23. - Google Patents

Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23.

Info

Publication number
MX2023004017A
MX2023004017A MX2023004017A MX2023004017A MX2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A
Authority
MX
Mexico
Prior art keywords
disease
antibody
crohn
treating crohn
doses
Prior art date
Application number
MX2023004017A
Other languages
English (en)
Spanish (es)
Inventor
Frederic Lavie
Bars Manuela Le
Michael Plotnick
Sheldon Sloan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023004017A publication Critical patent/MX2023004017A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4727Calcium binding proteins, e.g. calmodulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4737C-reactive protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2023004017A 2020-10-09 2021-10-07 Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23. MX2023004017A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089786P 2020-10-09 2020-10-09
US202163235188P 2021-08-20 2021-08-20
PCT/IB2021/059211 WO2022074603A1 (en) 2020-10-09 2021-10-07 Method for treating crohn's disease with anti-il12/il23 antibody

Publications (1)

Publication Number Publication Date
MX2023004017A true MX2023004017A (es) 2023-07-05

Family

ID=81078738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004017A MX2023004017A (es) 2020-10-09 2021-10-07 Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23.

Country Status (10)

Country Link
US (1) US20220112282A1 (https=)
EP (1) EP4225350A4 (https=)
JP (1) JP2023544620A (https=)
KR (1) KR20230084283A (https=)
CN (1) CN116348491A (https=)
AU (1) AU2021356282A1 (https=)
CA (1) CA3198413A1 (https=)
IL (1) IL301944A (https=)
MX (1) MX2023004017A (https=)
WO (1) WO2022074603A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471655B (zh) * 2020-03-19 2023-07-07 湖州正熙医学检验实验室有限公司 抗人il12/23稳转细胞株及其构建方法和应用
AU2024301395A1 (en) * 2023-07-21 2025-12-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of il-12 related biomarkers and il-12 specific blocking antibodies for the treatment of an autoimmune disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200197517A1 (en) * 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody

Also Published As

Publication number Publication date
CN116348491A (zh) 2023-06-27
IL301944A (en) 2023-06-01
CA3198413A1 (en) 2022-04-14
EP4225350A4 (en) 2025-01-22
KR20230084283A (ko) 2023-06-12
EP4225350A1 (en) 2023-08-16
WO2022074603A1 (en) 2022-04-14
US20220112282A1 (en) 2022-04-14
AU2021356282A1 (en) 2023-06-15
AU2021356282A9 (en) 2025-04-03
JP2023544620A (ja) 2023-10-24

Similar Documents

Publication Publication Date Title
MX2021003411A (es) Metodo seguro y eficaz para tratar la colitis ulcerosa con el anticuerpo anti-il12/il23.
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
CO2022002638A2 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
MX2019007779A (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
CL2024000739A1 (es) Métodos para tratar fabry en pacientes con una mutación en el gen gla
MX2023004017A (es) Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23.
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
BR112023019156A2 (pt) Inalador pressurizado dosimetrado e formulação para uso em um método para tratar uma reação alérgica aguda
AR112482A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry
MX2020009265A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
AR104771A1 (es) Inhalador de polvo seco
AR119430A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal
CL2022002423A1 (es) Métodos para tratar la enfermedad de fabry
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
MX2022013923A (es) Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23.
MX2022009987A (es) Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23.
MX2024005197A (es) Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23.
CR20220040A (es) Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab